192 related articles for article (PubMed ID: 19755913)
1. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care.
Weintrob AC; Grandits GA; Agan BK; Ganesan A; Landrum ML; Crum-Cianflone NF; Johnson EN; Ordóñez CE; Wortmann GW; Marconi VC;
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):574-80. PubMed ID: 19755913
[TBL] [Abstract][Full Text] [Related]
2. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care.
Hartzell JD; Spooner K; Howard R; Wegner S; Wortmann G
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):411-6. PubMed ID: 17195762
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of highly-active antiretroviral therapy by race/ethnicity.
Silverberg MJ; Wegner SA; Milazzo MJ; McKaig RG; Williams CF; Agan BK; Armstrong AW; Gange SJ; Hawkes C; O'Connell RJ; Ahuja SK; Dolan MJ;
AIDS; 2006 Jul; 20(11):1531-8. PubMed ID: 16847408
[TBL] [Abstract][Full Text] [Related]
4. Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.
Matthews PE; Le T; Delmar J; Okulicz JF
Int J STD AIDS; 2015 Nov; 26(13):951-9. PubMed ID: 25505041
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression.
OʼBryan TA; Agan BK; Tracy RP; Freiberg MS; Okulicz JF; So-Armah K; Ganesan A; Rimland D; Lalani T; Deiss RG; Tramont EC
J Acquir Immune Defic Syndr; 2018 Apr; 77(5):502-506. PubMed ID: 29315115
[TBL] [Abstract][Full Text] [Related]
7. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
8. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
[TBL] [Abstract][Full Text] [Related]
9. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
[TBL] [Abstract][Full Text] [Related]
10. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
[TBL] [Abstract][Full Text] [Related]
11. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project.
Ding H; Wilson CM; Modjarrad K; McGwin G; Tang J; Vermund SH
Arch Pediatr Adolesc Med; 2009 Dec; 163(12):1100-5. PubMed ID: 19996046
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.
van den Berg JB; Hak E; Vervoort SC; Hoepelman IM; Boucher CA; Schuurman R; Schneider MM
HIV Med; 2005 Sep; 6(5):299-306. PubMed ID: 16156876
[TBL] [Abstract][Full Text] [Related]
13. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
14. Virologic success in an urban HIV clinic: outcome at 12 months in patients who were HAART naïve.
Blanchard E; Klibanov OM; Axelrod P; Palermo B; Samuel R
HIV Clin Trials; 2008; 9(3):186-91. PubMed ID: 18547905
[TBL] [Abstract][Full Text] [Related]
15. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
Pence BW; Miller WC; Gaynes BN; Eron JJ
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):159-66. PubMed ID: 17146374
[TBL] [Abstract][Full Text] [Related]
16. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.
Tuboi SH; Harrison LH; Sprinz E; Albernaz RK; Schechter M
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):324-8. PubMed ID: 16249707
[TBL] [Abstract][Full Text] [Related]
17. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
; Patel D; Cortina-Borja M; Thorne C; Newell ML
Clin Infect Dis; 2007 Jun; 44(12):1647-56. PubMed ID: 17516411
[TBL] [Abstract][Full Text] [Related]
18. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
Mocroft A; Gill MJ; Davidson W; Phillips AN
J Acquir Immune Defic Syndr; 2000 Aug; 24(5):475-82. PubMed ID: 11035619
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy.
Deiss RG; Mesner O; Agan BK; Ganesan A; Okulicz JF; Bavaro M; Lalani T; O'Bryan TA; Bebu I; Macalino GE
Alcohol Clin Exp Res; 2016 Mar; 40(3):529-35. PubMed ID: 26916712
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
